Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 4th or Later Players Could Also Qualify for PMP If Post-Launch “True Clinical Utility” Premium Granted: MHLW
December 21, 2017
- Outline of Drug Pricing Reform Package
December 21, 2017
- Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
- (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
- Meiji-Kumamoto JV Becomes “Company that Can Succeed Worldwide”: Kaketsuken Chief
December 19, 2017
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
- Modified PMP Plan Reflects Some Industry Requests, but Not Sufficient: Chuikyo Pharma Rep
December 14, 2017
- Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
- MHLW Plans to Establish Related Information Service for Improving Drug Distribution
December 14, 2017
- Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
- LDP Lawmaker Prods MHLW to Include 4th or Later Drugs in PMP Coverage Too
December 13, 2017
- Japan and Taiwan to Conduct Pilot Project to Accelerate New Drug Reviews in Taiwan by Using PMDA’s Review Reports
December 13, 2017
- Abilify, Lixiana and Others under PMDA Risk Review
December 12, 2017
- MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
- First Generics for 8 APIs, AGs of Avapro, Talion Receive Listing on Dec. 8
December 8, 2017
- Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
- Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
- (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- ICH Completes Guidelines for Multiregional Clinical Trials; Could Accelerate Simultaneous Global Development
December 6, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…